Bio Medica Laboratories SME IPO GMP History
Bio Medica Laboratories SME IPO has been listed on May 29, 2026 at a listing price of ₹111.20, against the issue price of ₹139 — a loss of ₹27.8 (-20%). The GMP peaked at ₹4 on 22 May 2026 and reached a low of ₹0 on 25 May 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Bio Medica Laboratories SME IPO raised ₹52 Cr. through its IPO at a price band of ₹132 to ₹139 per share, with a lot size of 1000 shares. The IPO was open for subscription from 21 May 2026 to 25 May 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 3 Sep, 2:08 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 27 May 2026 | ₹ 2 | — | 1% | — | — |
| 26 May 2026 | ₹ 2 | ▲ | 1% | — | — |
| 25 May 2026 | ₹ 0 | ▼ | -- | — | — |
| 23 May 2026 | ₹ 2 | ▼ | 1% | — | — |
| 22 May 2026 | ₹ 4 | ▲ | 3% | — | — |
| 21 May 2026 | ₹ 0 | — | -- | — | — |
| 20 May 2026 | ₹ 0 | — | -- | — | — |
| 19 May 2026 | ₹ 0 | — | -- | — | — |
| 18 May 2026 | ₹ 0 | — | -- | — | — |
Bio Medica Laboratories SME IPO dates
Key dates from opening to listing. Today is 3 October.
- Open 21 May 2026
- Close 25 May 2026
- Allotment 26 May 2026
- Refund/credit 27 May 2026
- Listing 29 May 2026
Bio Medica Laboratories SME IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹139 |
|---|---|
| GMP-based estimate (pre-listing) | ₹141 (+1.4%) |
| Listing gain / loss | −₹27.8 per share |
| Listing date | 29 May, 2026 |
| Actual listing price | ₹111.20 (-20%) |
Is Bio Medica Laboratories SME IPO GMP reliable?
Grey market premium for Bio Medica Laboratories SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Bio Medica Laboratories SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Bio Medica Laboratories SME IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Bio Medica Laboratories SME IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Bio Medica Laboratories SME IPO
Bio Medica Laboratories is an Indian pharmaceutical company engaged in the manufacturing and marketing of a wide range of healthcare and medicinal products. The company has built its presence in the pharmaceutical sector through quality-focused manufacturing practices and a diversified product portfolio catering to hospitals, clinics, and retail healthcare markets. Over the years, it has expanded its operations by focusing on customer relationships, product reliability, and compliance with industry standards.
The company operates on a business model centred around the development, production, and distribution of pharmaceutical formulations and healthcare solutions across multiple therapeutic segments. Its product offerings include tablets, capsules, syrups, injections, and other medical formulations supplied through distributors and healthcare networks. The business is promoted by experienced industry professionals who focus on expanding market reach, improving manufacturing capabilities, and strengthening the company’s position in the domestic pharmaceutical industry.
Frequently asked
What is the GMP of Bio Medica Laboratories SME IPO?
The current Grey Market Premium (GMP) of Bio Medica Laboratories SME IPO is ₹ 2.
What is the Kostak Price of Bio Medica Laboratories SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Bio Medica Laboratories SME IPO is not available.
What is the Subject to Sauda Price of Bio Medica Laboratories SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Bio Medica Laboratories SME IPO?
Bio Medica Laboratories SME IPO listed on May 29, 2026 at ₹111.20, against the issue price of ₹139 — a loss of -20%.
How did the GMP of Bio Medica Laboratories SME IPO trend before listing?
The GMP of Bio Medica Laboratories SME IPO was stable in its final days before listing. The GMP peaked at ₹4 on 22 May 2026. View the day-wise table above for the complete GMP history.
Explore Bio Medica Laboratories SME IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
